M Hakama1, U H Stenman, A Aromaa, J Leinonen, T Hakulinen, P Knekt. 1. Department of Public Health, Helsinki University, Tampere University School of Public Health, Finnish Cancer Registry, University Hospital of Helsinki, The National Public Health Institute, Helsinki, Finland.
Abstract
PURPOSE: We investigate the validity of prostate specific antigen (PSA) as a screening test for prostate cancer. MATERIALS AND METHODS: A registry of serum samples drawn from 1968 to 1976 from 21,387 men was linked to the Finnish Cancer Registry. During followup from 1968 to 1991, 104 prostate cancers were identified. A matched case control design with incidence density sampling and nested in the serum sample bank was applied, and PSA was assessed. RESULTS: The estimated sensitivity of the test was 44% and specificity 94% at a cutoff of 4.0 microg./l. in the total material. The sensitivity had improved to 86% in patients diagnosed in 5 years after the sample drawing. The test had a better sensitivity (93%) and specificity (96%) in men younger than 65 years at the time of the sample drawing compared to those older. The sensitivity further improved to 100% with a cutoff of 2.5 microg./l. CONCLUSIONS: PSA is a valid screening test for prostate cancer, which compares favorably with mammography for breast cancer. However, until an effect on mortality has been shown, routine screening cannot be recommended.
PURPOSE: We investigate the validity of prostate specific antigen (PSA) as a screening test for prostate cancer. MATERIALS AND METHODS: A registry of serum samples drawn from 1968 to 1976 from 21,387 men was linked to the Finnish Cancer Registry. During followup from 1968 to 1991, 104 prostate cancers were identified. A matched case control design with incidence density sampling and nested in the serum sample bank was applied, and PSA was assessed. RESULTS: The estimated sensitivity of the test was 44% and specificity 94% at a cutoff of 4.0 microg./l. in the total material. The sensitivity had improved to 86% in patients diagnosed in 5 years after the sample drawing. The test had a better sensitivity (93%) and specificity (96%) in men younger than 65 years at the time of the sample drawing compared to those older. The sensitivity further improved to 100% with a cutoff of 2.5 microg./l. CONCLUSIONS:PSA is a valid screening test for prostate cancer, which compares favorably with mammography for breast cancer. However, until an effect on mortality has been shown, routine screening cannot be recommended.
Authors: Timothy C Brand; Javier Hernandez; Edith D Canby-Hagino; Joseph W Basler; Ian M Thompson Journal: Curr Urol Rep Date: 2006-05 Impact factor: 3.092
Authors: Sam De Coster; Gudrun Koppen; Marc Bracke; Carmen Schroijen; Elly Den Hond; Vera Nelen; Els Van de Mieroop; Liesbeth Bruckers; Maaike Bilau; Willy Baeyens; Greet Schoeters; Nik van Larebeke Journal: Environ Health Date: 2008-06-03 Impact factor: 5.984
Authors: L Määttänen; M Hakama; T L J Tammela; M Ruutu; M Ala-Opas; H Juusela; P Martikainen; U-H Stenman; A Auvinen Journal: Br J Cancer Date: 2007-01-15 Impact factor: 7.640